Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug AU409 enters first human tests for tough liver cancers

NCT ID NCT05791448

First seen Feb 02, 2026 · Last updated Apr 29, 2026 · Updated 15 times

Summary

This early-phase trial tests a new drug called AU409 in people with advanced liver cancer or other cancers that have spread to the liver. The main goals are to find the safest dose and see what side effects occur. About 36 adults whose cancer has not responded to standard treatments will take part. The study is run by the University of Southern California.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Los Angeles County-USC Medical Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • USC / Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.